{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T08:05:45Z","timestamp":1750925145773},"reference-count":42,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2019.7505","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T11:43:26Z","timestamp":1555587806000},"source":"Crossref","is-referenced-by-count":5,"title":["Biosimilars in dermatology: The wind of change (Review)"],"prefix":"10.3892","author":[{"given":"Maria","family":"Constantin","sequence":"first","affiliation":[{"name":"The Second Department of Dermatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Cristea","sequence":"additional","affiliation":[{"name":"Petroleum and Gas University of Ploiesti, Medical Office, 100680 Ploiesti, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Taranu","sequence":"additional","affiliation":[{"name":"Department of Oral Dermatology, \u2018Gr. T. Popa\u2019 University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefana","family":"Bucur","sequence":"additional","affiliation":[{"name":"The Second Department of Dermatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Traian","family":"Constantin","sequence":"additional","affiliation":[{"name":"Department of Urology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Dinu","sequence":"additional","affiliation":[{"name":"The Second Department of Dermatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Jinga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, \u2018Carol Davila\u2019 Central Military Emergency University Hospital, 010825 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iuliana","family":"Nita","sequence":"additional","affiliation":[{"name":"The Second Department of Dermatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2019,4,18]]},"reference":[{"key":"key20200713100345_b1-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"e0190147","DOI":"10.1371\/journal.pone.0190147","article-title":"Policies for biosimilar uptake in Europe: An overview","volume":"12","author":"Moorkens","year":"2017","journal-title":"PLoS One"},{"key":"key20200713100345_b2-etm-0-0-7505","first-page":"1","article-title":"The concept of biosimilars: From characterization to evolution - A narrative review","volume":"22","author":"Farhat","year":"2017","journal-title":"Oncologist"},{"key":"key20200713100345_b3-etm-0-0-7505","first-page":"119","article-title":"Escaping the economic turn down through performing employees, creative leaders and growth driver capabilities in the Romanian pharmaceutical industry","volume":"59","author":"Ratiu","year":"2011","journal-title":"Farmacia"},{"key":"key20200713100345_b4-etm-0-0-7505","unstructured":"European Medicines Agency: Glossaryhttp:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/document_library\/landing\/glossary.jsp&mid=&startLetter=AMarch102018"},{"key":"key20200713100345_b5-etm-0-0-7505","first-page":"335","article-title":"Immunologic responses to therapeutic biologic agents","volume":"18","author":"Purcell","year":"2008","journal-title":"J Investig Allergol Clin Immunol"},{"key":"key20200713100345_b6-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.clinthera.2011.12.005","article-title":"Biosimilars: Impact of biologic product life cycle and European experience on the regulatory trajectory in the United States","volume":"34","author":"Ahmed","year":"2012","journal-title":"Clin Ther"},{"key":"key20200713100345_b7-etm-0-0-7505","first-page":"5","article-title":"Biosimilars and the extrapolation of indications for inflammatory conditions","volume":"11","author":"Tesser","year":"2017","journal-title":"Biologics"},{"key":"key20200713100345_b8-etm-0-0-7505","unstructured":"National Health ServiceWhat is a Biosimilar Medicine?https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2015\/09biosimilar-guide.pdfJune102018"},{"key":"key20200713100345_b9-etm-0-0-7505","unstructured":"Food Drug AdministrationBiologics Price Competition and Innovation Act of 2009; Meetings on User Fee Program for Biosimilar and Interchangeable Biological Product Applications; Request for Notification of Stakeholder Intention To Participatehttps:\/\/www.federalregister.gov\/documents\/2010\/12\/08\/2010-30713\/biologics-price-competition-and-innovation-act-of-2009-meetings-on-user-fee-program-for-biosimilarJune102018"},{"key":"key20200713100345_b10-etm-0-0-7505","unstructured":"US Food and Drug AdministrationBiosimilar and Interchangeable Productshttps:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/Biosimilars\/ucm580419.htmJune102018"},{"key":"key20200713100345_b11-etm-0-0-7505","unstructured":"European MedicinesAgencyQuestions and answers on generic medicineshttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Medicine_QA\/2009\/11\/WC500012382.pdfJune102018"},{"key":"key20200713100345_b12-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/CCID.S91691","article-title":"Biosimilars: Potential implications for clinicians","volume":"9","author":"Eleryan","year":"2016","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"key20200713100345_b13-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00296-016-3444-0","article-title":"Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology","volume":"36","author":"Mysler","year":"2016","journal-title":"Rheumatol Int"},{"key":"key20200713100345_b14-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1111\/bcp.13076","article-title":"Clinical trials for authorized biosimilars in the European Union: A systematic review","volume":"82","author":"Mielke","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"key20200713100345_b15-etm-0-0-7505","first-page":"270","article-title":"Biosimilars part 1: Proposed regulatory criteria for FDA approval","volume":"38","author":"Ventola","year":"2013","journal-title":"P T"},{"key":"key20200713100345_b16-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"iv14","DOI":"10.1093\/rheumatology\/kex278","article-title":"The process defines the product: what really matters in biosimilar design and production?","volume":"56","author":"Vulto","year":"2017","journal-title":"Rheumatology"},{"key":"key20200713100345_b17-etm-0-0-7505","first-page":"89","article-title":"Storage and handling of biopharmaceuticals: Problems and solutions: A workshop discussion","volume":"8","author":"Crommelin","year":"2003","journal-title":"Eur J Hosp Pharm Sci Pract"},{"key":"key20200713100345_b18-etm-0-0-7505","first-page":"p383","article-title":"Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies","author":"Shimasaki","year":"2014","edition":"1st"},{"key":"key20200713100345_b19-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nrd3746","article-title":"Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars","volume":"11","author":"Berkowitz","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"key20200713100345_b20-etm-0-0-7505","unstructured":"European MedicinesAgencyGuideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing processhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003935.pdfMarch52018"},{"key":"key20200713100345_b21-etm-0-0-7505","unstructured":"European MedicinesAgencyGuideline on Immunogenicity Assessment of Biotechnology - Derived Therapeutic Proteinshttps:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-first-version_en.pdfDecember132007"},{"key":"key20200713100345_b22-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3109\/09546634.2015.1054782","article-title":"Biologics and biosimilars","volume":"26","author":"Patel","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"key20200713100345_b23-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40259-014-0088-z","article-title":"Drift, evolution, and divergence in biologics and biosimilars manufacturing","volume":"28","author":"Ramanan","year":"2014","journal-title":"BioDrugs"},{"key":"key20200713100345_b24-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"vi3","DOI":"10.1093\/ndt\/gfh1092","article-title":"Factors influencing the immunogenicity of therapeutic proteins","volume":"20","author":"Schellekens","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"key20200713100345_b25-etm-0-0-7505","unstructured":"European MedicinesAgencyProduction and Quality Control of Monoclonal Antibodieshttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003444.pdfMarch52018"},{"key":"key20200713100345_b26-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2217\/imt.10.67","article-title":"Anti-TNF-\u03b1 agents in the treatment of immune-mediated inflammatory diseases: Mechanisms of action and pitfalls","volume":"2","author":"Silva","year":"2010","journal-title":"Immunotherapy"},{"key":"key20200713100345_b27-etm-0-0-7505","first-page":"443","article-title":"Role of angiotensin converting enzyme (ACE) inhibitors in hypertension and cardiovascular protection management","volume":"62","author":"Tantu","year":"2014","journal-title":"Farmacia"},{"key":"key20200713100345_b28-etm-0-0-7505","first-page":"47","article-title":"Skin cancer between myth and reality, yet ethically constrained","volume":"12","author":"Gheunca-Solovastru","year":"2014","journal-title":"Rev Rom Bioet"},{"key":"key20200713100345_b29-etm-0-0-7505","first-page":"1241","article-title":"Assessment of dermal papillary and microvascular parameters in psoriasis vulgaris using in vivo reflectance confocal microscopy","volume":"15","author":"Batani","year":"2018","journal-title":"Exp Ther Med"},{"key":"key20200713100345_b30-etm-0-0-7505","first-page":"1191","article-title":"In vivo imaging techniques for psoriatic lesions","volume":"55","author":"C\u0103runtu","year":"2014","journal-title":"Rom J Morphol Embryol"},{"key":"key20200713100345_b31-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2217\/bmm.14.76","article-title":"Proteomics focusing on immune markers in psoriatic arthritis","volume":"9","author":"Caruntu","year":"2015","journal-title":"Biomarkers Med"},{"key":"key20200713100345_b32-etm-0-0-7505","first-page":"767","article-title":"Acitretin treatment in psoriasis may influence the cell membrane fluidity","volume":"60","author":"Negrei","year":"2012","journal-title":"Farmacia"},{"key":"key20200713100345_b33-etm-0-0-7505","first-page":"607","article-title":"Qualitative and quantitative determination of methotrexate polyglutamates in erythrocytes by high performance liquid chromatography","volume":"66","author":"Negrei","year":"2015","journal-title":"Rev Chim"},{"key":"key20200713100345_b34-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40257-017-0341-6","article-title":"Safety of adalimumab dosed every week and every other week: Focus on patients with hidradenitis suppurativa or psoriasis","volume":"19","author":"Ryan","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"key20200713100345_b35-etm-0-0-7505","first-page":"766","article-title":"Investigation relevance of methotrexate polyglutamates in biological systems by high performance liquid chromatography","volume":"66","author":"Negrei","year":"2015","journal-title":"Rev Chim"},{"key":"key20200713100345_b36-etm-0-0-7505","first-page":"704","article-title":"Assessment of some oxidative stress parameters in methotrexate treated psoriasis patients","volume":"62","author":"Boda","year":"2014","journal-title":"Farmacia"},{"key":"key20200713100345_b37-etm-0-0-7505","first-page":"15","article-title":"Review of biosimilars of Adalimumab","volume":"65","author":"Kaushik","year":"2017","journal-title":"J Assoc Physicians India"},{"key":"key20200713100345_b38-etm-0-0-7505","first-page":"918","article-title":"Original clinical experience and approach to treatment study with interleukine 12\/23 inhibitor in moderate-to-severe psoriasis patients","volume":"64","author":"Olteanu","year":"2016","journal-title":"Farmacia"},{"key":"key20200713100345_b39-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jim.2017.03.007","article-title":"Establishment of the first WHO International Standard for etanercept, a TNF receptor II Fc fusion protein: Report of an international collaborative study","volume":"447","author":"Wadhwa","year":"2017","journal-title":"J Immunol Methods"},{"key":"key20200713100345_b40-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00296-014-3080-5","article-title":"Etanercept biosimilars","volume":"35","author":"Azevedo","year":"2015","journal-title":"Rheumatol Int"},{"key":"key20200713100345_b41-etm-0-0-7505","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s40265-015-0503-x","article-title":"Adalimumab: A review in chronic plaque psoriasis","volume":"75","author":"Burness","year":"2015","journal-title":"Drugs"},{"key":"key20200713100345_b42-etm-0-0-7505","first-page":"57","article-title":"Biosimilars: An update on clinical trials (review of published and ongoing studies)","volume":"25","author":"Olteanu","year":"2017","journal-title":"Acta Dermatovenerol Croat"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T09:04:25Z","timestamp":1594631065000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2019.7505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,18]]},"references-count":42,"URL":"https:\/\/doi.org\/10.3892\/etm.2019.7505","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,18]]}}}